FTB Advisors Inc. reduced its position in shares of Sanofi SA (NYSE:SNY) by 25.6% during the 3rd quarter, Holdings Channel reports. The firm owned 3,570 shares of the company’s stock after selling 1,229 shares during the quarter. FTB Advisors Inc.’s holdings in Sanofi were worth $1,225,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Institute for Wealth Management LLC. grew its holdings in shares of Sanofi by 27.4% during the second quarter. Institute for Wealth Management LLC. now owns 31,936 shares of the company’s stock worth $1,278,000 after purchasing an additional 6,860 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Sanofi by 15.1% during the second quarter. Van ECK Associates Corp now owns 361,195 shares of the company’s stock worth $14,451,000 after purchasing an additional 47,420 shares during the last quarter. Nomura Holdings Inc. grew its holdings in shares of Sanofi by 51.8% during the second quarter. Nomura Holdings Inc. now owns 50,726 shares of the company’s stock worth $2,030,000 after purchasing an additional 17,310 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Sanofi by 32.0% during the second quarter. Signaturefd LLC now owns 10,266 shares of the company’s stock worth $411,000 after purchasing an additional 2,486 shares during the last quarter. Finally, Providence Capital Advisors LLC grew its holdings in shares of Sanofi by 46.0% during the second quarter. Providence Capital Advisors LLC now owns 30,016 shares of the company’s stock worth $1,201,000 after purchasing an additional 9,460 shares during the last quarter. Institutional investors own 7.53% of the company’s stock.
Several analysts recently commented on SNY shares. Citigroup upgraded Sanofi from a “neutral” rating to a “buy” rating in a report on Friday, August 10th. Wolfe Research started coverage on Sanofi in a report on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Zacks Investment Research cut Sanofi from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. Bank of America upgraded Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Monday, September 10th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, October 15th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $49.50.
Shares of SNY stock opened at $45.59 on Friday. Sanofi SA has a one year low of $37.43 and a one year high of $46.25. The company has a market capitalization of $111.91 billion, a P/E ratio of 14.57, a P/E/G ratio of 2.53 and a beta of 0.70. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40.
Sanofi (NYSE:SNY) last announced its earnings results on Wednesday, October 31st. The company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.09. The business had revenue of $9.39 billion for the quarter, compared to analysts’ expectations of $9.10 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm’s revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.71 earnings per share. As a group, sell-side analysts anticipate that Sanofi SA will post 3.09 EPS for the current fiscal year.
WARNING: This piece of content was reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/10/ftb-advisors-inc-trims-stake-in-sanofi-sa-sny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.